NCT01206387已完成3 期
A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 120
- 主要终点
- Clinical Success
研究概览
简要总结
efficacy study in patients with moderate to severe plaque psoriasis.
详细描述
A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients with Moderate to Severe Plaque Psoriasis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant, non-lactating female 18 years of age or older.
- •Have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the body surface area (BSA).
- •Have a combined total lesion severity score (TLSS) of ≥ 7 for the Target Lesion.
- •Have a plaque elevation score ≥ 3 of (moderate) for the Target Lesion.
- •The Target Lesion must have an area of at least 5 cm².
- •Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity.
排除标准
- •Patient has current diagnosis of other types of psoriasis other than stable plaque psoriasis (i.e. acute, guttate, erythrodermic, exfoliative or pustular psoriasis) or has psoriasis of any kind of the face or scalp that will require active treatment during the study. Nonprescription antipsoriatic shampoos will be allowed during the study when applied solely to the scalp.
- •Patient has a history of psoriasis that has been unresponsive to topical corticosteroid therapy.
- •In the Investigator's opinion, the patient has other dermatological conditions, such as atopic or contact dermatitis, that may interfere with the clinical assessments of the signs and symptoms of psoriasis.
- •Patient has a history of allergy or sensitivity to corticosteroids or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the patient or the results of the study.
- •Patient has been treated within 12 weeks (or five half lives, whichever is less) prior to the first dose of study drug with any biological therapies for psoriasis.
- •Patient has received any systemic steroids within 4 weeks of the first dose of the study drug. The use of inhaled or intranasal corticosteroids is acceptable as long as usage has been stable for at least 2 weeks prior to the first dose of study drug and will be continued during the study.
- •Patients who have used any topical antipsoriatic agents of any kind or any topical corticosteroids for any reason within 2 weeks prior to first use of study drug. Nonprescription antipsoriatic shampoos used only on the scalp will be allowed during the study.
- •Receipt of any drug as part of a research study within 30 days prior to first dosing.
研究组 & 干预措施
active product
Experimental
Desoximetasone Spray 0.25%
干预措施: Desoximetasone Spray 0.25% (Drug)
placebo comparator
Placebo Comparator
vehicle
干预措施: placebo comparator (Drug)
结局指标
主要结局
Clinical Success
时间窗: 28 days
A patient is considered a Clinical Success if the Physician's Global Assessment (PGA) is 0 (clear) or 1 (almost clear).
Treatment Success
时间窗: 28 days
A patient is considered a Treatment Success for the Target Lesions if the target lesion has a score of 0 or 1 on the Target Lesion Severity Score (TLSS)for each of each of the three signs and symptoms (erythema, scaling and plaque elevation).
次要结局
- Mean Change From Baseline in Physician Global Assessment (PGA) Score at Day 28 Using ITT.(Baseline and day 28)
- Mean Change From Baseline in Total Lesion Severity Scale (TLSS) (ITT)(Baseline and day 28)
- Mean Change From Baseline in Percent Body Surface Area (%BSA) Affected at Day 28(Baseline and day 28)
研究者
相似试验
已完成
3 期
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque PsoriasisPsoriasisNCT01873677Maruho North America Inc.537
已完成
3 期
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque PsoriasisPsoriasisNCT01878461Maruho North America Inc.542
已完成
3 期
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body PsoriasisPsoriasisNCT01139580Stiefel, a GSK Company363
Unknown
1 期
Safety and Efficacy of UC-MSCs in Patients With Plaque PsoriasisModerate and Severe Plaque PsoriasisNCT03424629Tianjin Ever Union Biotechnology Co., Ltd.57
已完成
2 期
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765PsoriasisNCT00205465Vertex Pharmaceuticals Incorporated64